Finally, KRAS activation leads to RAS-dependent tumour growth via the RAL pathway and vesicle trafficking via the tumour invasion and metastasis-inducing protein 1 (TIAM1-RAC1) pathway [98, 99]. The gene discussed is RAC1; the disease is neoplasm.